ClinicalTrials.Veeva

Menu

Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

C

Central South University

Status

Enrolling

Conditions

Gastric Cancer

Treatments

Diagnostic Test: The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer

Study type

Observational

Funder types

Other

Identifiers

NCT06543108
FAPI-001

Details and patient eligibility

About

This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age over 18 years old;
  2. Diagnosed as a patient with gastric cancer;
  3. Receive FAPI PET/CT and FDG PET/CT imaging within one week;
  4. Perform serum tumor marker testing one week before and after scanning

Exclusion criteria

  1. History of other malignant tumors;
  2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;
  3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;
  4. Patients with unorganized pathology or incomplete clinical data

Trial contacts and locations

1

Loading...

Central trial contact

Hui Ye

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems